Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

NCT04685135 is registered in ClinicalTrials.gov with Mirati Therapeutics Inc. as lead sponsor.

NCT NCT04685135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04685135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Study of MRTX849 Versus Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation
Lead sponsor
Mirati Therapeutics Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 23, 2021
Completion date
October 30, 2026
Enrollment
453 (actual)
Sites
380

Conditions

As the registry lists them; a condition with its own page is linked.

advanced non small cell lung cancer, metastatic non small cell lung cancer